Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Marcus Davidsson

Marcus Davidsson

Postdoctoral fellow

Marcus Davidsson

A comparison of AAV-vector production methods for gene therapy and preclinical assessment

Author

  • Marcus Davidsson
  • Matilde Negrini
  • Swantje Hauser
  • Alexander Svanbergsson
  • Marcus Lockowandt
  • Giuseppe Tomasello
  • Fredric P. Manfredsson
  • Andreas Heuer

Summary, in English

Adeno Associated Virus (AAV)-mediated gene expression in the brain is widely applied in the preclinical setting to investigate the therapeutic potential of specific molecular targets, characterize various cellular functions, and model central nervous system (CNS) diseases. In therapeutic applications in the clinical setting, gene therapy offers several advantages over traditional pharmacological based therapies, including the ability to directly manipulate disease mechanisms, selectively target disease-afflicted regions, and achieve long-term therapeutic protein expression in the absence of repeated administration of pharmacological agents. Next to the gold-standard iodixanol-based AAV vector production, we recently published a protocol for AAV production based on chloroform-precipitation, which allows for fast in-house production of small quantities of AAV vector without the need for specialized equipment. To validate our recent protocol, we present here a direct side-by-side comparison between vectors produced with either method in a series of in vitro and in vivo assays with a focus on transgene expression, cell loss, and neuroinflammatory responses in the brain. We do not find differences in transduction efficiency nor in any other parameter in our in vivo and in vitro panel of assessment. These results suggest that our novel protocol enables most standardly equipped laboratories to produce small batches of high quality and high titer AAV vectors for their experimental needs.

Department/s

  • Behavioural Neuroscience Laboratory
  • Neural Plasticity and Repair
  • MultiPark: Multidisciplinary research focused on Parkinson´s disease
  • CNS Gene Therapy

Publishing year

2020

Language

English

Publication/Series

Scientific Reports

Volume

10

Issue

1

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Neurosciences

Status

Published

Research group

  • Behavioural Neuroscience Laboratory
  • Neural Plasticity and Repair
  • CNS Gene Therapy

ISBN/ISSN/Other

  • ISSN: 2045-2322